B
Bull
Bull · 25%INVA
$20.18
Szenariopreis
$21.080
+0.314 (+1.49%)Zum Schluss
Loading chart…
- High
- 21.175
- Open
- 20.970
- VWAP
- 21.07
- Vol
- 798.74K
- Mkt Cap
- 1.01B
- Low
- 20.940
- Amount
- 16.83M
- EV/EBITDA, TTM
- 3.89
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
AI analysis of Innoviva Inc (INVA)
holdInnoviva Inc is currently a hold. The stock is priced at $20.97, which is below the average analyst price target of $38, indicating potential upside. However, the RSI is at 44.53, suggesting it is nearing oversold territory but not yet a strong buy signal. The recent loss of $83.4 million in Q2 is a significant risk that could weigh on investor sentiment.
Bewertungskennzahlen
The current forward P/E ratio for Innoviva Inc (INVA) is 10.67, compared to its 5-year average forward P/E of 12.17.
Alphio AI Price Scenarios for INVA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding INVA
Event-Zeitleiste
News
9.508-05Yahoo FinanceInnoviva Reports $83.4 Million Loss in Q2
9.506-26NASDAQ.COMBayer Shares Surge 17% Following Supreme Court Ruling
6.505-29FoolDauntless Investment Group Increases Stake in Innoviva
9.505-06seekingalphaInnoviva Q1 Earnings Beat Expectations
3.004-09MarketbeatThree Affordable Small-Cap Stocks That Deserve Another Look
INVA FAQ — answered by Alphio AI
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Innoviva Inc is currently a hold. The stock is priced at $20.97, which is below the average analyst price target of $38, indicating potential upside. However, the RSI is at 44.53, suggesting it is nearing oversold territory but not yet a strong buy signal. The recent loss of $83.4 million in Q2 is a significant risk that could weigh on investor sentiment.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.